Weiss Ratings Reiterates "Sell (D-)" Rating for Bausch + Lomb (NYSE:BLCO)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for Bausch + Lomb, indicating ongoing concerns about the company's stock performance.
• The stock has seen mixed analyst opinions, with Morgan Stanley and Wells Fargo raising their price targets to $13.00 and $15.00 respectively, while the average price target remains at $15.70.
• Bausch + Lomb reported a marginal increase in quarterly revenue, achieving $1.28 billion, which slightly exceeded analyst estimates, although it faced a negative net margin of 5.58%.

Bausch + Lomb (NYSE:BLCO - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

Other research analysts have also issued research reports about the stock. Morgan Stanley lifted their price target on shares of Bausch + Lomb from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Zacks Research upgraded shares of Bausch + Lomb to a "hold" rating in a research report on Tuesday, August 12th. Citigroup restated a "neutral" rating on shares of Bausch + Lomb in a research report on Tuesday, October 7th. Wells Fargo & Company raised their price objective on shares of Bausch + Lomb from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Finally, The Goldman Sachs Group assumed coverage on shares of Bausch + Lomb in a research note on Wednesday, October 1st. They issued a "neutral" rating and a $16.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $15.70.

Bausch + Lomb Price Performance

Bausch + Lomb stock traded down $0.26 during mid-day trading on Friday, hitting $15.52. The company's stock had a trading volume of 209,773 shares, compared to its average volume of 726,164. The company has a quick ratio of 0.98, a current ratio of 1.55 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $5.49 billion, a P/E ratio of -19.89, a P/E/G ratio of 1.72 and a beta of 0.63. Bausch + Lomb has a twelve month low of $10.45 and a twelve month high of $20.94. The stock's fifty day moving average price is $14.92 and its two-hundred day moving average price is $13.42.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.25 billion. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. Research analysts forecast that Bausch + Lomb will post 0.74 earnings per share for the current year.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLCO. Trexquant Investment LP boosted its stake in shares of Bausch + Lomb by 5.8% during the 1st quarter. Trexquant Investment LP now owns 20,255 shares of the company's stock valued at $294,000 after buying an additional 1,108 shares during the period. Woodline Partners LP boosted its stake in shares of Bausch + Lomb by 0.5% during the 1st quarter. Woodline Partners LP now owns 312,823 shares of the company's stock valued at $4,536,000 after buying an additional 1,436 shares during the period. Blue Trust Inc. boosted its stake in shares of Bausch + Lomb by 58.5% during the 2nd quarter. Blue Trust Inc. now owns 4,502 shares of the company's stock valued at $59,000 after buying an additional 1,662 shares during the period. Ridgewood Investments LLC acquired a new stake in shares of Bausch + Lomb during the 2nd quarter valued at $26,000. Finally, Gabelli Funds LLC boosted its stake in shares of Bausch + Lomb by 0.5% during the 2nd quarter. Gabelli Funds LLC now owns 444,000 shares of the company's stock valued at $5,776,000 after buying an additional 2,000 shares during the period. Institutional investors and hedge funds own 11.07% of the company's stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.